The Life Sciences team advised Nimbus Therapeutics in its sale to Takeda of Nimbus Lakshmi, Inc. and its tyrosine kinase 2 (Tyk2) inhibitor program for $4 billion upfront and up to $2 billion in commercial-related milestone payments.

Upon completion of the acquisition, Nimbus Lakshmi, Inc. will become a wholly-owned subsidiary of Takeda. Nimbus Therapeutics will retain ownership of its other research and development subsidiaries. Takeda will be solely responsible for future development and commercialization of NDI-034858, an allosteric Tyk2 inhibitor discovered and developed by Nimbus that is being evaluated in Phase 2b clinical trials for the treatment of multiple autoimmune diseases, and other Tyk2 inhibitors. Closing of the acquisition is contingent on completion of review under applicable antitrust laws.

Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. Nimbus Therapeutics combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus Therapeutics’ pipeline includes clinical-stage programs targeting Tyk2 and HPK1 (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, inflammatory and autoimmune conditions and metabolic diseases.

Goodwin has a long-standing relationship with Nimbus Therapeutics, including work on its most recent $105 million investment round, collaborations with Celgene, Eli Lilly and other pharmaceutical companies, and its $1.2 billion sale of Nimbus Apollo to Gilead Sciences.

The cross-disciplinary Goodwin team that advised Nimbus was led by Bill Collins, Sarah Solomon, Erini Svokos, Yasin Akbari, EA Weeks, Kim Maruncic and Alexandra Haas, with support from Dan Karelitz and Erika Pey (Tax), Arman Oruc, Paul Jin, Charlie Stewart and Elliot Silver (Antitrust), Matt Wetzel, Elizabeth Mulkey and Heath Ingram (Regulatory), Amy Josselyn (Global Trade) and Chris Denn, Kathleen Kean, Gabriela Morales-Rivera, Christopher Huntsman, Katie Hand, Kat Stavrianidis, Elliot Horlick, David Sackstein, Alex Hernandez, and Daniela Sanchez (Life Sciences).

For more details, read the press release and articles in Endpoints News, Fierce Biotech, Reuters, Seeking Alpha and The Deal.